Petras Michael B. Jr. sold $5.4M of SHC

Petras Michael B. Jr. (Executive Chairman) sold 294,515 shares of Sotera Health Co (SHC) at $18.50 ($5.45M total) on 2026-08-17.

Original reporting
SEC EDGAR · Petras Michael B. Jr.
Published Aug 19, 2026, 8:24 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 19, 2026, 8:58 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SHC
Bearish
medium confidence
Mentioned
$SHC
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SHCBearishLow
01

Why it matters

The insider sale reduces the insider's ownership, which may be interpreted by investors as a negative signal.

02

Market read

Primary insider sell news; modest impact on SHC stock.

03

What to watch

Potential upcoming corporate actions or personal tax planning not disclosed.

Relevance 6/10Novelty 5/10Timing: filing date 2026-08-19

Background

Form 4 filings disclose insider transactions; this is the first public report of this sale.

Company-level read

Ticker impact

$SHCBearishMedium confidence
Context

Executive Chairman Michael B. Petras Jr. sold 294,515 shares for $5.45 M, reducing his stake to 397,912 shares.

Expected impact

Short-term downward pressure; price may dip 1‑2% on news.

Evidence & confidence

Insider sales by a top officer are material, but the amount is modest relative to market cap; impact likely limited.

Market effects

Minimal; health‑care sector unlikely to be affected.

None

Low

Counterpoint

The sale could be unrelated to confidence; could be a planned liquidity event.

Key entities

  • Sotera Health Co

    Public health‑care services provider (ticker SHC).

  • Michael B. Petras Jr.

    Executive Chairman and director of Sotera Health.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

MedAI 8/10

Sotera Health Company Q3 2026 Earnings Call Summary

Sotera Health reported Q3 2026 earnings, with Sterigenics and Nelson Labs driving performance. Nordion saw revenue decline due to cobalt-60 timing. Management noted European market softness. Guidance reaffirmed, with flat Q4 Sterigenics revenue and reduced 2027 CapEx. Nelson Labs' growth expected to moderate. Net leverage improved to 2.9x, leading to a credit rating upgrade. Litigation and FX headwinds noted.

$SHCHighAI 8/10

Sotera Health (SHC) Q3 2026 Earnings Call Transcript

Sotera Health (SHC) reported Q3 2026 revenue growth of 4.4% to $325M and adjusted EBITDA growth of 4% to $171M. Sterigenics grew 8.2%, Nelson Labs 9.2%, and Nordion declined 11.5%. The company reaffirmed its 2026 revenue and adjusted EBITDA outlook, expecting 5.25-6.75% and 5.75-7.25% growth, respectively. Adjusted EBITDA margins expanded sequentially by 100 basis points to 52.5%.

$SHCHighAI 8/10

Why is Sotera Health stock sliding today?

Sotera Health (SHC) shares fell 9.5% despite Q3 2026 earnings beat (EPS $0.29, revenue $324.9M) due to cautious guidance. Revenue declined 12% in the Nordion segment. JPMorgan downgraded to Underweight with a $17 target, and insiders sold 1.29M shares. The S&P 500 and Nasdaq rose, but Sotera's decline was company-specific.

$SHCMed

What Sotera Health (SHC) Said on Its Q3 Earnings Call

Sotera Health (SHC) reported Q3 earnings, noting softness in the European medical-device market. Sterigenics expects 6% constant-currency growth in Q4, while Nelson Labs saw 8.8% revenue growth. Nordion revenue fell 12.4% due to shipment timing. The company reaffirmed its 2026 outlook for 5.25% to 6.75% revenue growth and maintained its adjusted EBITDA forecast.